Entacapone is an Antioxidant More Potent than Vitamin C and Vitamin E for Scavenging of Hypochlorous Acid and Peroxynitrite, and the Inhibition of Oxidative Stress-Induced Cell Death

ABCDEF 1,2 Aaron Y. Chen
ABCDE 1 Jian-Ming Lü
CDG 1 Qizhi Yao
ACDEFG 1 Changyi Chen

Background: Entacapone (ENT), a clinical drug for the treatment of Parkinson’s disease, has been shown to have antioxidant effects, but little is known about its antioxidant mechanisms. The objective of the current study was to determine the antioxidant activity of ENT against different species of oxidants and compared it with that of vitamin C and vitamin E. We also determined the effect of ENT on oxidative stress-induced cell death in human umbilical vein endothelial cells (HUVECs).

Material/Methods: The total antioxidant activities of ENT, vitamin C and vitamin E were determined with a standard DPPH-scavenging assay. Specific assays to determine ENT’s scavenging activity on hypochlorous acid (HOCl), peroxynitrite (ONOO⁻), and hydrogen peroxide (H₂O₂), and the chelating effect on Fe(II) were used. H₂O₂-induced cell death in HUVECs was determined with the MTT assay.

Results: ENT (10 and 20 µM) scavenged 60% and 83% of DPPH activity, respectively. These percentages were greater than those resulting from using the same concentrations of vitamin C and vitamin E. ENT’s HOCl-scavenging activity was concentration-dependent and 8 to 20 times stronger than those of vitamin C and vitamin E. ENT’s ONOO⁻-scavenging activity was 8% to 30% stronger than that of vitamin C. However, ENT, vitamin C, and vitamin E were not able to directly scavenge H₂O₂, and did not show any chelating effect on Fe(II). Importantly ENT, but not vitamin C or vitamin E, inhibited H₂O₂-induced cell death in HUVECs.

Conclusions: ENT is an antioxidant that can scavenge toxic HOCl and ONOO⁻ species and inhibit oxidative stress-induced cell death more effectively than vitamin C and vitamin E. ENT may have new clinical applications as an antioxidant in the treatment of ROS-induced diseases including cardiovascular disease, cancer, and neurodegenerative diseases.

MeSH Keywords: Antioxidants • Endothelial Cells • Entacapone • Peroxynitrous Acid

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/896462
Background

Oxidative stress refers to a state in which the levels of reactive oxygen species (ROS) and reactive nitrogen species (RNS) in the human body are higher than their physiological concentrations. These ROS and RNS include superoxide anion (O$_2^-$), hydrogen peroxide (H$_2$O$_2$), hydroxyl radical (OH$^-$), nitric oxide (NO), peroxynitrite (ONOO$^-$), and hypochlorous acid (HOCl). ROS comprise a heterogeneous population of molecules that can be interconverted from one form to another [1–3]. Homeostasis of ROS is highly regulated by multiple factors including oxidation processes and antioxidant mechanisms. Oxidative stress can result from overproduction of ROS and/or insufficient antioxidant molecules and enzymes. ROS can be generated from the electron transport chain (ETC) as by-products of glucose or free fatty acid metabolic processes in the mitochondria, and can be produced in the cytoplasm, peroxisomes and endoplasmic reticulum, via oxidation reactions with several enzymes [1,2]. Additionally, ROS can be produced from food additives, drugs, ionizing radiation, photo-oxidation, tobacco smoke, and many other environment pollutants. The human body has a variety of antioxidant mechanisms including those involving endogenous molecules such as thiols and glutathione (GSH), and enzymes such as superoxide dismutase (SOD), catalase, and glutathione peroxidase (GPx). Other main sources of antioxidants are diet or supplements such as vitamin E (Vit E), vitamin C (Vit C), carotenoids and trace metals (selenium, manganese, and zinc), and flavonoids. These antioxidant mechanisms can inhibit ROS formation or promote free radical scavenging. Physiological levels of ROS are involved in physiological responses as part of signaling processes, gene regulation, and defense mechanisms against pathogens [4]. However, excessive production of ROS and/or insufficient activity of antioxidant defense mechanisms may result in oxidative stress, which could cause the damage to DNA, lipids, proteins, and carbohydrates, and abnormal gene expression [5], thereby contributing to many inflammatory and chronic diseases including cancer, atherosclerosis, hypertension, diabetes mellitus, Alzheimer’s disease, Parkinson’s disease, and rheumatoid arthritis [6] (Figure 1). For instance, NO can reversibly bind to heme proteins; O$_2^-$ can react with proteins, changing their redox state [7]; and H$_2$O$_2$, O$_2^-$, and NO species can be converted to OH, ONOO$^-$, and HOCl species, which are more toxic. In addition, the Fenton reaction between ferrous ions and H$_2$O$_2$ yields OH; the reaction of O$_2^-$ with NO yields ONOO$^-$; and the enzymatic reaction from H$_2$O$_2$ and Cl$^-$ forms HOCl [8–10].

Antioxidants reduce oxidative stress; therefore, they may prevent or reduce the risk of oxidative stress-related pathological conditions. Indeed, some reports have shown the beneficial effects of oral antioxidants on the survival of women with breast cancer [11] and on the improvement of endothelial function in patients with atherosclerosis, diabetes, and heart failure [12]. However, conflicting data are often reported [13–15]. The reasons for this are complex and multifactorial. For instance, most clinical trials examined a single antioxidant and specific mechanisms of ROS-mediated diseases are not completely understood. Measuring ROS accurately in patients is still challenging. In addition, different antioxidants may have different antioxidant mechanisms, pharmacokinetics, and tissue distribution. Considering the complex multifactorial nature of ROS-mediated chronic diseases, it could be more appropriate to treat these diseases with combination therapy of multiple antioxidants. The rational for discovering new antioxidant properties in established drugs is that it would increase the pool of drugs for combination therapy for ROS-mediated diseases. Examples of established drugs with pleiotropic antioxidant effects are statins, ACE-inhibitors, and AT1-receptor blockers [16]. In this study, we determined the antioxidant activity of ENT, an established drug for the treatment of Parkinson’s disease.

Oxidative stress plays an important role in Parkinson’s disease [17–19]. The main pathology of this disease is the presence of a decreased number of dopamine-secreting cells in the brain. Currently, there is no cure for Parkinson’s disease, but medications and other treatments can provide relief from the symptoms. For example, L-DOPA is the most commonly used drug which, when converted into dopamine, diminishes the motor symptoms [20]. However, L-DOPA can be degraded by the enzyme catechol-O-methyltransferase (COMT) in the body, reducing L-DOPA effectiveness. To increase the effect of L-DOPA, a COMT inhibitor, entacapone (ENT), is often used. Previous studies have found that ENT has antioxidant effects [21–23]; however, its antioxidant mechanisms are not yet known. Our study has addressed this important issue by determining ENT’s antioxidant activities against diverse forms of ROS and comparing them with those of the most commonly used antioxidants, Vit C and Vit E. We determined the antioxidant effects and mechanisms of ENT in a cell free system, and examined the effect of ENT on oxidative stress-induced cell death in human umbilical vein endothelial cells (HUVECs). This study may provide a significant rationale for using ENT as a power antioxidant in combination therapy for ROS-induced diseases, including Parkinson’s disease, cancer, and cardiovascular diseases.

Material and Methods

Reagents

The following reagents were obtained from Sigma-Aldrich (St Louis, MO): ENT, 1,1-Diphenyl-2-picrylhydrazyl radical (DPPH), pyruvate, Vit C, Vit E, 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl-tetrazolium bromide (MTT), iron (III) chloride (FeCl$_3$), EDTA, ferrous ammonium sulfate, hydrogen peroxide (H$_2$O$_2$),
sodium hypochlorite and ferrozone. We purchased the following reagents from VWR: 2,2’-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) and nitroblue tetrazolium (NBT). Dihydrorhodamine (DHR123) was obtained from Cayman Chemical (Ann Arbor, MI). Hydroxyphenyl fluorescein (HPF, Hydroxyl/Peroxynitrite Detection Kit™) was obtained from Cell Technology, Inc (Mountain View, CA).

### DPPH scavenging assay

We measured the ability of ENT to scavenge stable radical cationic DPPH spectrophotometrically by monitoring the reduction in absorbance at 515 nm, as we previously described [3,24]. Briefly, various concentrations of antioxidants (ENT, Vit C, and Vit E) were added separately to DPPH solutions, and absorption readings were recorded with a UV-Vis spectrophotometer (Agilent Technologies Inc, Santa Clara, CA). DPPH has a deep violet color in solution, and it becomes colorless or pale yellow as it is neutralized by antioxidants. The absorbance of each reading at 515 nm was corrected with a blank (water) control. The change in the optical absorption at 515 nm in the solution of DPPH with each antioxidant was calculated against the DPPH alone control. Final data were presented as percentage of DPPH scavenging activity.

### HOCl scavenging assay

The HOCl-scavenging assay is based on the inhibition of the oxidation of thio-2-nitrobenzoic acid (TNB) to 5,5’-dithio-bis(2-nitrobenzoic acid) (DTNB), induced by HOCl. TNB has a chromophore that has maximal absorbance at 412 nm, but DTNB is colourless [3]. Briefly, HOCl and TNB were freshly prepared as previously described [24]. We determined the HOCl-scavenging activity of ENT by measuring the inhibition of HOCl-mediated oxidation of TNB to DTNB. We calculated the percentage of HOCl-scavenging activity for each antioxidant according to the difference of absorbance readings between the reaction of HOCl and TNB and the reaction of HOCl, TNB, and antioxidant. We then compared the scavenging activity of ENT with that of Vit C and Vit E.

### Peroxynitrite scavenging assay

Peroxynitrite (ONOO⁻) readily oxidizes dihydrorhodamine (DHR 123), a fluorescence molecule, to rhodamine 123. This reaction can be measured with a spectrophotometer at 502 nm. We determined the ability of ENT to scavenge ONOO⁻ by measuring the inhibition of ONOO⁻-induced oxidation of DHR 123 to rhodamine 123. For this assay, we prepared fresh batches of antioxidants (ENT, Vit C, and Vit E) were added separately to DHR solutions, and absorbance readings were recorded with a spectrophotometer at 502 nm. The change in the optical absorption at 502 nm was corrected with a blank (water) control. The difference of absorbance readings between the reaction of ONOO⁻ and antioxidants and ONOO⁻ alone control was calculated against the ONOO⁻ alone control. Final data were presented as percentage of peroxynitrite scavenging activity.

---

**Figure 1.** Overview of ROS. The free radical $O_2^-$ can be produced from endogenous and exogenous sources: it can be converted to ONOO⁻ through reaction with NO to HO⁻ through transition Fe(II), and to $H_2O_2$ via SOD enzymatic reaction. $H_2O_2$ can be converted to HOCl through an MPO enzymatic reaction and to HO· through the Fenton reaction. ONOO⁻ can be converted to HO⁻. SOD, CAT, and GPx are major antioxidant enzymes in the body. The physiological levels of ROS play important roles in signal transduction pathways; however, excessive high levels of ROS damage biomolecules (DNA, RNA, lipids, and carbohydrates), prevent infection by viruses and bacteria, and contribute to chronic inflammation and diseases. ROS – reactive oxygen species; RNS – reactive nitrogen species; ETC – electron transport chain; XO – xanthine oxidase; MPO – myeloperoxidase; NOS – nitric oxide synthase; LOX – leukotriene; COX – cyclooxygenase; CYP – cytochrome; NO – nitric oxide; $O_2^-$ – superoxide radical anion; ONOO⁻ – peroxynitrite; HO⁻ – hydroxyl radical; $H_2O_2$ – hydrogen peroxide; HOCl – hypochlorous acid; $H_2O$ – water; $O_2$ – oxygen; SOD – superoxide dismutase; CAT – catalase; GPx – glutathione peroxidase; NOX – NOX (NADPH oxidase).
of H$_2$O$_2$ and NaNO$_2$, as previously described [3]. We determined the concentration of ONOO$^-$ before each experiment with spectrophotometric readings at 302 nm. We measured the ONOO$^-$-scavenging activity of each antioxidant by calculating absorbance differences between the reaction of ONOO$^-$ and DHR 123 and the reaction of ONOO$^-$, DHR 123, and antioxidant. Then, we compared ENT’s ONOO$^-$ scavenging activity with that of Vit C. Due to a solubility issue, Vit E could not be used in this assay.

**H$_2$O$_2$ scavenging assay**

To determine the ability of ENT to scavenge H$_2$O$_2$, we mixed a solution of 75 μM H$_2$O$_2$ with solutions of different concentrations of ENT (1:1 v/v) and incubated the mixtures for 1 hour at room temperature. Then, we mixed H$_2$O$_2$ with the FOX reagent and measured the absorbance at 560 nm [24]. Scavenging of H$_2$O$_2$ by the antioxidant leads to a reduced absorbance. We then compared the ability of ENT to scavenge H$_2$O$_2$ with that of Vit C and Vit E. Pyruvate was used as a positive control.

**Fe(II) chelating assay**

The ability of ENT to chelate Fe$^{2+}$ ions was measured with a method previously described [24]. Briefly, 0.2 mL of solutions containing increasing concentrations of ENT or other antioxidants was added individually to 0.74 mL of H$_2$O. This mixture was then combined with 0.02 mL of 2 mM FeCl$_2$ and 0.04 mL of 5 mM ferozine. After 20 minutes, we read the absorbance at 562 nm. A reduction in absorbance indicated higher chelating activity. EDTA was used as a positive control.

**Oxidative stress-induced cell death**

HUVECs (Lonza Inc, Alendale, NJ) were grown in EGM-2 culture medium (Lonza) at 37°C in a humidified atmosphere with 5% CO$_2$. Fifth passages of HUVECs were used for this study. We determined oxidative stress-induced cell death with the MTT assay, as previously described [25]. Briefly, HUVECs (5×10$^3$ cells/well) were seeded into 96-well plates in regular growth medium and maintained in this medium for one day. We then pre-treated the cells with DMSO (1%), ENT (20 µM), Vit C (20 µM) or Vit E (20 µM) for 2 hours, and incubated them in 0.7 mM H$_2$O$_2$ for 4 hours. Subsequently, we treated the cells with MTT (250 μg/mL) at 37°C for 4 hours and lysed them in 100 μL lysis buffer. After solubilizing MTT to a blue formazin dye with DMSO, we read the absorbance at 570 nm. The cells incubated with control medium were considered to be 100% viable.

**Results**

**ENT is a DPPH scavenger more potent than Vit C or Vit E.**

DPPH is one of the most commonly used reagents to determine the total antioxidant activity for potential antioxidants. Chemically, the odd electron of the nitrogen atom in DPPH is reduced by receiving a hydrogen atom from antioxidants [26]. Using the DPPH assay we determined that ENT at 10 µM and 20 µM significantly reduced DPPH activity by 60% and 83%, respectively. At 20 µM, Vit C and Vit E reduced DPPH activity by 40% and 63%, respectively (Figure 2). Thus, ENT has a potent DPPH-scavenging activity, which is stronger than that of Vit C and Vit E.

**ENT scavenges hypochlorous acid more effectively than Vit C and Vit E**

HOCl is a highly toxic species of ROS and it reacts with a wide variety of biomolecules including proteins, lipids, and DNA. We performed an HOCl-scavenging assay based on HOCl being able to oxidize TNB to DTNB. ENT strongly inhibited HOCl-induced...
TNB oxidation in a concentration-dependent manner (1, 2, 5, 10 and 20 µM). For example, at a lower concentration (2 µM), ENT was able to scavenge 40% of HOCl, while Vit C and Vit E scavenged 3% and 2% of HOCl, respectively, under the same conditions (Figure 3A). At a higher concentration (10 µM), ENT scavenged 88% of HOCl, while Vit C and Vit E scavenged 11% and 10%, respectively (Figure 3B). Thus, ENT can effectively scavenge HOCl in a cell-free system with an activity that is 8 to 20 times stronger than that of Vit C and Vit E.

**ENT scavenges peroxynitrite more effectively than Vit C**

The reaction of NO with superoxide forms peroxynitrite (ONOO\(^-\)), which is an oxidant much more powerful than superoxide [27,28]. ONOO\(^-\) reacts directly with amino acids and lipids to form nitrotyrosine, nitrotryptophan, and nitrated lipids [29]. The current in vitro ONOO\(^-\)-scavenging assay is based on the ability of ONOO\(^-\) to oxidize the fluorescence molecule dihydrorhodamine (DHR 123). ENT at the concentrations of 5 µM, 10 µM, and 20 µM effectively scavenged 61%, 73%, and 76% of ONOO\(^-\), respectively. The effect of ENT was stronger than that of Vit C by 8% to 30%, at the same concentrations (Figure 4). Vit E was not studied in this assay because of its solubility issue.

**ENT does not directly scavenge hydrogen peroxide nor chelate Fe(II)**

Hydrogen peroxide (H\(_2\)O\(_2\)) is a precursor of several ROS such as OH\(^-\) and HOCl. The transition metal ion Fe(II) possesses the ability to perpetuate the formation of free radicals by gain or
loss of electrons. Therefore, agents that chelate metal ions could play an antioxidant role in reducing the formation of ROS. In the current study, we determined whether ENT had H$_2$O$_2$-scavenging and Fe(II)-chelating activities. Neither ENT (20 µM), Vit C, nor Vit E showed significant H$_2$O$_2$-scavenging activity with the sensitive Fox reagent method (Figure 5). Pyruvate was used as a positive control because it is able to directly scavenge H$_2$O$_2$ [30]. In our experiment, pyruvate (10 µM) scavenged 23% of H$_2$O$_2$. In addition, ENT, Vit C, and Vit E showed no Fe(II)-chelating activity, while the positive control with EDTA (10 µM) chelated 82% of Fe(II), under the same experiment condition (Figure 6). Thus, ENT has no H$_2$O$_2$-scavenging or Fe(II)-chelating activities in vitro.

**ENT significantly inhibits oxidative stress-induced cell death in HUVECs**

Excessive ROS leads to oxidative damage and cell death. One of the major contributors to oxidative damage is H$_2$O$_2$. H$_2$O$_2$ is produced when O$_2^-$, a byproduct of cellular metabolism, is simultaneously reduced and oxidized (dismutated). H$_2$O$_2$ readily diffuses out of the mitochondria and reacts with ferrous iron (Fe$^{2+}$) or other transition metal ions to produce OH$, which are highly toxic. H$_2$O$_2$ is also quickly converted to toxic HOCl species. It is well known that H$_2$O$_2$-mediated oxidative stress can cause cell death [31,32]. We tested whether ENT could inhibit H$_2$O$_2$-induced toxicity in HUVECs. Indeed, treatment with H$_2$O$_2$ induced 48% of cell death in HUVECs; however, if the cells were pre-treated with ENT (20 µM), cell death was 16% (Figure 7). Under the same experimental conditions, Vit C and Vit E did not protect HUVECs from of H$_2$O$_2$-induced cell death. Thus, ENT significantly prevents HUVECs from oxidative stress-induced cell death.

**Discussion**

In the current study, we have explored the antioxidant capabilities of ENT, a clinical drug for Parkinson’s disease. ENT is a potent scavenger of DPPH, a free radical indicator, as well as other transition metal ions to produce OH$, which are highly toxic. H$_2$O$_2$ is also quickly converted to toxic HOCl species. It is well known that H$_2$O$_2$-mediated oxidative stress can cause cell death [31,32]. We tested whether ENT could inhibit H$_2$O$_2$-induced toxicity in HUVECs. Indeed, treatment with H$_2$O$_2$ induced 48% of cell death in HUVECs; however, if the cells were pre-treated with ENT (20 µM), cell death was 16% (Figure 7). Under the same experimental conditions, Vit C and Vit E did not protect HUVECs from of H$_2$O$_2$-induced cell death. Thus, ENT significantly prevents HUVECs from oxidative stress-induced cell death.
For instance, the reaction of ONOO\textsuperscript{-} oxidant that can damage a wide array of molecules in cells. In biological systems, peroxynitrite (ONOO\textsuperscript{-}) is formed by the reaction of the free radical O\textsuperscript{2-} with NO. ONOO\textsuperscript{-} is a powerful oxidant that can damage a wide array of molecules in cells. For instance, the reaction of ONOO\textsuperscript{-} with amino acids results in the formation of nitrated amino acids, such as 3-nitrotyrosine. ONOO\textsuperscript{-}-mediated protein modification is irreversible and may have a pathological effect on cellular function. ONOO\textsuperscript{-} can also oxidize unsaturated fatty acids in biological membranes to form nitrated fatty acids such as oleic, linolenic, and arachidonic acids [46,47]. Furthermore, ONOO\textsuperscript{-} can react with DNA and produce damaged DNA molecules such as 8-hydroxy-2-deoxyguanosine (8-OHdG) and 8-nitroguanine [48]. In addition, ONOO\textsuperscript{-} is able to oxidize the NOS cofactor BH4, thereby leading to eNOS uncoupling and O\textsuperscript{2-} production [49]. ONOO\textsuperscript{-} can be decomposed to yield HO\textsuperscript{2-}, independently on the presence of transition metals [50]. This evidence indicates that ONOO\textsuperscript{-} is highly toxic to cells and strongly supports the need for antioxidants that can potentially scavenge ONOO\textsuperscript{-}. In this study, we provide a contribution to satisfy that need. We show that ENT effectively scavenges ONOO\textsuperscript{-} in an in vitro system under the same conditions in which Vit C is less effective. Vit E could not be compared with ENT because assay conditions limited the solubility of Vit E. In other ROS scavenging assays, ENT, Vit C, and Vit E did not scavenge H\textsubscript{2}O\textsubscript{2} and did not have any Fe(II)-chelating activity.

Vit C and Vit E as antioxidants have been used extensively in the clinic, with mixed outcomes. For example, intra-arterial administration of high doses of Vit C resulted in improved endothelium-dependent vasodilation in the forearm microcirculation of hypertensive patients [51]. However, prolonged oral administration of Vit C did not result in improved endothelial function in hypertensive patients. Vit E supplementation had no effect on endothelial function in aged individuals [51]. Large clinical antioxidant trials of Vit C or Vit E have also failed to show that of Vit C and Vit E. These results suggest that ENT could be considered a powerful antioxidant that can scavenge ONOO\textsuperscript{-} in vitro, for instance the detection of 3-chlorotyrosine for proteins, 2-chloradipic acid for lipids, and 8-chloroadenine for DNA [43–45]. In our study, we show that ENT has an antioxidant effect against HOCl that is dose-dependent and between 13 and 20 times stronger than that of Vit C and Vit E. These results suggest that ENT could be indicated for the treatment of HOCl-induced diseases.

We then determined the antioxidant activity of ENT on HOCl. HOCl is a strong oxidant that results from MPO-mediated peroxidation of chloride ions from H\textsubscript{2}O\textsubscript{2} in activated neutrophils and macrophages, and contributes to the destruction of bacteria and viruses. HOCl reacts strongly with many biologically important molecules, such as DNA, proteins, lipids, and carbohydrates. The reactivity of HOCl with most substrates exceeds that of other ROS, such as H\textsubscript{2}O\textsubscript{2} and ONOO\textsuperscript{-}, by several orders of magnitude [35]. HOCl has been implicated in inflammation as a mediator of oxidative tissue damage and cellular dysfunction leading to the initiation and acceleration of many diseases such as cystic fibrosis [36], chronic obstructive pulmonary disease [37], gout [38], atherosclerosis [39], rheumatoid arthritis [40], and cancers [41,42]. Several biomarkers have been used for detecting the production of HOCl in vivo, for instance the detection of 3-chlorotyrosine for proteins, 2-chloradipic acid for lipids, and 8-chloroadenine for DNA [43–45]. In our study, we show that ENT has an antioxidant effect against HOCl that is dose-dependent and between 13 and 20 times stronger than that of Vit C and Vit E. These results suggest that ENT could be indicated for the treatment of HOCl-induced diseases.

In biological systems, peroxynitrite (ONOO\textsuperscript{-}) is formed by the reaction of the free radical O\textsuperscript{2-} with NO. ONOO\textsuperscript{-} is a powerful oxidant that can damage a wide array of molecules in cells. For instance, the reaction of ONOO\textsuperscript{-} with amino acids results in the formation of nitrated amino acids, such as 3-nitrotyrosine. ONOO\textsuperscript{-}-mediated protein modification is irreversible and may have a pathological effect on cellular function. ONOO\textsuperscript{-} can also oxidize unsaturated fatty acids in biological membranes to form nitrated fatty acids such as oleic, linolenic, and arachidonic acids [46,47]. Furthermore, ONOO\textsuperscript{-} can react with DNA and produce damaged DNA molecules such as 8-hydroxy-2-deoxyguanosine (8-OHdG) and 8-nitroguanine [48]. In addition, ONOO\textsuperscript{-} is able to oxidize the NOS cofactor BH4, thereby leading to eNOS uncoupling and O\textsuperscript{2-} production [49]. ONOO\textsuperscript{-} can be decomposed to yield HO\textsuperscript{2-}, independently on the presence of transition metals [50]. This evidence indicates that ONOO\textsuperscript{-} is highly toxic to cells and strongly supports the need for antioxidants that can potentially scavenge ONOO\textsuperscript{-}. In this study, we provide a contribution to satisfy that need. We show that ENT effectively scavenges ONOO\textsuperscript{-} in an in vitro system under the same conditions in which Vit C is less effective. Vit E could not be compared with ENT because assay conditions limited the solubility of Vit E. In other ROS scavenging assays, ENT, Vit C, and Vit E did not scavenge H\textsubscript{2}O\textsubscript{2} and did not have any Fe(II)-chelating activity.

Vit C and Vit E as antioxidants have been used extensively in the clinic, with mixed outcomes. For example, intra-arterial administration of high doses of Vit C resulted in improved endothelium-dependent vasodilation in the forearm microcirculation of hypertensive patients [51]. However, prolonged oral administration of Vit C did not result in improved endothelial function in hypertensive patients. Vit E supplementation had no effect on endothelial function in aged individuals [51]. Large clinical antioxidant trials of Vit C or Vit E have also failed

Figure 7. The effects of ENT, Vit C, and Vit E on the inhibition of oxidative stress-induced cell death in HUVECs. To determine the ability of ENT to protect HUVECs from cell death induced by oxidative stress, HUVECs were pre-treated with 20 µM ENT, Vit C, Vit E or control reagents and then challenged with a high concentration of H\textsubscript{2}O\textsubscript{2} (0.7 mM) for 4 hours. Cell viability was determined with the MTT assay. n=3. ** P<0.01 comparing negative control with H\textsubscript{2}O\textsubscript{2} treated cells. ## P<0.01 comparing H\textsubscript{2}O\textsubscript{2} and H\textsubscript{2}O\textsubscript{2}+ENT-treated cells.
to show significant cardiovascular benefits [52], and it is controversial whether Vit C and Vit E have therapeutic effects in cancers [53–55]. Different antioxidants may act in different ways. Vit C is water-soluble and reacts rapidly with a variety of ROS; it can play an antioxidant role in the cytosol and the extracellular matrix. However, Vit C may have a prooxidant activity and reducetrivalent iron to its divalent form, which enhances ROS formation [56,57]. On the other hand, Vit E is lipophilic and located in the biological membrane where it can react with lipid peroxyl radicals produced during lipid peroxidation process. Our results and those of others strongly support research to develop new antioxidants with different antioxidant mechanisms and to consider combination therapy of multiple antioxidants for ROS-induced diseases, such as cardiovascular disease and cancer.

ROS can modify biomolecules, such as proteins, DNA, and lipids, leading to cell death and disease formation. For example, high levels of ROS-mediated oxidative stress can damage the structure and functions of endothelial cells, and contribute to pathogenesis of hypertension, diabetes, inflammation and atherosclerosis [58,59]. The assays of H$_2$O$_2$-induced death of endothelial cells or neuronal cells are commonly used in vitro models for determining antioxidant effects on oxidative stress [31,32,60,61]. Using these assays, other have shown that H$_2$O$_2$ is highly permeable to cell membrane [62] and can increase production of O$_2^-$ by activating NADPH oxidase and eNOS uncoupling [63,64]. H$_2$O$_2$ can also be converted to HOCl by MPO, and O$_2^-$ is readily converted to OHOO$_2^-$ through reaction with ON. Both HOCl and OHOO$_2^-$ are highly toxic to cells. To test ENT’s antioxidant properties against HOCl and OHOO$_2^-$, we first used a cell-free system and found that ENT has a scavenging activity that is more potent than that of Vit C and Vit E. Therefore, we expected that ENT would be able to protect cells from an H$_2$O$_2$ challenge. Indeed, ENT (20 µM) effectively reduced H$_2$O$_2$-induced cell death in HUVECs by 67%, while, under the same experimental conditions, Vit C and Vit E did not show a protective effect. These data strongly encourage considering ENT as a clinical antioxidant medicine.

ENT is a drug currently used in the treatment of Parkinson’s disease (PD). ENT inhibits catechol-O-methyltransferase (COMT) which results in increased levels of levodopa/carbidopa in the brain, enhancing its effectiveness. Previous in vitro investigations showed that ENT can effectively inhibit alpha-synuclein and beta-amyloid oligomerization and fibrillogenesis, which play a central role in the pathogenesis of PD and related synucleinopathies. The catechol moiety of ENT is essential for its anti-amyloidogenic activity [65]. In addition, a previous study has shown that ENT has an antioxidant effect on alkaline phosphatase (ALP) oxidation in vitro. In this assay, ALP is oxidized by 2,2'-azobis(2-methylpropionamidine) dihydrochloride (AAPH) and loses its enzymatic function of hydrolyzing 4-methylumbelliferyl phosphate (4-MUP) to fluorescent 4-methylumbelliferone (4-MU). ENT can protect ALP from AAPH-induced oxidation and functional loss [21]. ENT is also able to scavenge NO in an in vitro assay [23]. In this study, we show the total antioxidant capacity of ENT in the DPPH assay. We also show, for the first time, that ENT can directly scavenge HOCl and ONOO$^-$. A previous study has shown that ENT has Fe(III)-chelating activity, as shown by the electromotive force titration method [22]; however, the functional role of this Fe(III)-chelating property may be an effective antioxidant [66,67]. In the current study, we observed no Fe(II) chelating activity for ENT, Vit C, or Vit E.

**Conclusions**

We show, for the first time, that the antioxidant mechanisms of the clinical drug ENT are involved in its ability to scavenge HOCl and ONOO$^-$, two highly toxic ROS. ENT’s antioxidant potential is significantly higher than that of Vit C and Vit E, as shown by the DPPH-, the HOCl-, and the ONOO$^-$-scavenging assays. Functionally, ENT effectively protects HUVECs from oxidative stress-induced cell death. These new data suggest that ENT may have new indications for the treatment and/or prevention of oxidative stress-induced diseases, including cardiovascular disease, cancer, neurodegeneration disease, and inflammatory disease. New clinical trials to confirm these new indications of ENT are warranted.

**Acknowledgment**

The authors would like to thank Ana María Rodríguez, PhD, a member of the Michael E. DeBakey Department of Surgery Research Core Team, for her editorial assistance during the preparation of this manuscript.

**Conflict of interest statement**

No conflict of interest.
References:

1. Niedzielska E, Smaga I, Gawlik M et al: Oxidative stress in neurodegenerative diseases. Mol Neurobiol, 2015; [Epub ahead of print]

2. Blesa I, Trigo-Damas I, Quiroga-Varea A, Jackson-Lewis VR: Oxidative stress and Parkinson’s disease. Front Neuroanat, 2015; 9: 91

3. Lü JM, Lin PH, Yao Q, Chen C. Chemical and molecular mechanisms of antioxidants: experimental approaches and model systems. J Cell Mol Med, 2010; 14: 840–60

4. Casas-Grajales S, Muriel P. Antioxidants in liver health. World J Gastrointest Pharmacol Ther, 2015; 6: 59–72

5. Pereira C, Grácio D, Teixeira JP, Magro F: Oxidative stress and DNA damage: Implications in inflammatory bowel disease. Inflamm Bowel Dis, 2015; 21: 2403–17

6. Espinosa-Diez C, Miguel V, Mennerich D et al: Antioxidant responses and cellular adjustments to oxidative stress. Redox Biol, 2015; 6: 183–97

7. Arthur M, Kowsali-Saunders P, Gurney S et al: Reduction of ferricytochrome C may underestimate superoxide production by monocytes. J Immunol Methods, 1987, 98: 63–69

8. Cadet J, Wagner JR: Oxidatively generated base damage to cellular DNA by hydroxyl radical and one-electron oxidants: similarities and differences. Arch Biochem Biophys, 2014; 557: 47–54

9. Salgo MG, Squadrito GL, Pryor WA: Peroxynitrite causes apoptosis in rat thymocytes. Biochem Biophys Res Commun, 1995; 215: 1111–18

10. Panasenko OM, Eugina SV, Diromina ES et al: Hypochlorite induces lipoproteins and lipid peroxidation in blood phospholipid liposomes. Free Radic Biol Med, 1995; 19: 133–40

11. Harris HR, Orsini N, Wolk A. Vitamin C and survival among women with breast cancer: A meta-analysis. Eur J Cancer, 2014; 50: 1223–31

12. Ashor AW, Lara J, Mathers JC, Siervo M: Effect of vitamin C on endothelial function in healthy and disease: a systematic review and meta-analysis of randomised controlled trials. Atherosclerosis, 2014; 235: 9–20

13. Lonn E, Bosch J, Yusuf S, HOPE and HOPE-TOO Trial Investigators et al: Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA, 2005; 293: 2355–65

14. Mallet RT, Sun J: Antioxidant properties of myocardial fuels. Mol Cell Biochem, 2003; 253: 103–11

15. Kwok HH, Ng WY, Yang MS et al: The ginsenoside protopanaxatriol protects endothelial cells from hydrogen peroxide-induced cell injury and cell death by modulating intracellular redox status. Free Radic Biol Med, 2010; 48: 437–45

16. Choi YI, Lee MK, Lee YI et al: Inhibition of hydrogen peroxide-induced endothelial apoptosis by 2’,4’,7-trihydroxyflavone, a flavonoid form. J Med Food, 2004; 7: 408–16

17. Sharma OP, Bhat TR: DPPH antioxidant assay revisited. Food Chemistry, 2009, 113: 1202–5

18. Kedare SB, Singh RP: Genes and development of DPPH method of antioxidant assay. J Food Sci Technol, 2011; 48: 412–22

19. Winterbourn CC: Reconciling the chemistry and biology of reactive oxygen species. Nat Chem Biol, 2008; 4: 278–86

20. Thomson E, Brennan S, Senthilmohan R et al: Identifying peroxidases and their oxidants in the early pathology of cystic fibrosis, Free Radic Biol Med, 2010; 49: 1354–60

21. Quint JK, Wedzicha JA: The neutrophil in chronic obstructive pulmonary disease. J Allergy Clin Immunol, 2007; 119: 1065–71

22. Martin WL, Harper JL: Inflame inflammation and resolution in acute gut. Immunol Cell Biol, 2010; 88: 15–19

23. Nicholls SJ, Hazen SL: Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol, 2005; 25: 1102–11

24. Stamp LK, Khallilova I, Tarr JM et al: Myeloperoxidase and oxidative stress in rheumatoid arthritis. Rheumatology, 2012; 51: 1796–803

25. Panasenko OM, Gorudko IV, Sokolov AV: Hypochlorous acid as a precursor of active hypochlorite and their oxidants in the early pathology of cystic fibrosis, Free Radic Biol Med, 2010; 49: 1354–60

26. Trostchansky A, Bonilla L, Gonzalez-Perilli L, Rubbo H: Nitro-fatty acids: for better or worse? Arterioscler Thromb Vasc Biol, 2005; 25: 1102–11

27. Alenius M, Lonn E, Bosch J, Yusuf S, HOPE and HOPE-TOO Trial Investigators et al: Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA, 2005; 293: 2355–65

28. Beckman JS, Beckman TW, Chen J et al: Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA, 1990; 87: 1620–24

29. Pacher P, Beckman JS, Liaudet L: Nitric oxide and peroxynitrite in health and disease. Physiol Rev, 2007; 87: 315–424

30. Panasenko OM, Gorudko IV, Sokolov AV: Hypochlorous acid as a precursor of active hypochlorite and their oxidants in the early pathology of cystic fibrosis, Free Radic Biol Med, 2010; 49: 1354–60

31. Ghiadoni L, Taddei S, Virdis A: Hypertension and endothelial dysfunction: a therapeutic approach. Curr Vasc Pharmacol, 2012; 10: 42–60

32. Siervo M, Lara J, Chowdhury S et al: Effects of the dietary approach to stop hypertension (DASH) diet on cardiovascular risk factors: a systematic review and meta-analysis. Br J Nutr, 2014; 28: 1–15

33. Lin J, Cook NR, Albert C et al: Vitamins C and E and beta carotene supplementation and cancer: a randomized controlled trial. J Natl Cancer Inst, 2009; 101: 14–23

34. Carr AC, Vissers MC, Cook JS: The effect of intravenous vitamin C on cancer and chemotherapy-related fatigue and quality of life. Front Oncol, 2014; 4: 283
55. Masri OA, Chalhoub JM, Sharara AI: Role of vitamins in gastrointestinal diseases. World J Gastroenterol, 2015; 21: 5191–209
56. Carr A, Frei B: Does vitamin C act as a pro-oxidant under physiological conditions? FASEB J, 1999; 13: 1007–24
57. Du J, Cullen JJ, Buettner GR: Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim Biophys Acta, 2012; 1826: 443–57
58. Feletou M, Vanhoutte PM: Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol, 2006; 291: H885–1002
59. Li JM, Shah AM: Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol Regul Integr Comp Physiol, 2004; 287: R1014–30
60. Zhao R, Fang SH, Lin KN et al: Pranlukast attenuates hydrogen peroxide-induced necrosis in endothelial cells by inhibiting oxygen reactive species-mediated collapse of mitochondrial membrane potential. J Cardiovasc Pharmacol, 2011; 57: 479–88
61. Togar B, Türkez H, Stefano AD et al: Zingiberene attenuates hydrogen peroxide-induced toxicity in neuronal cells. Hum Exp Toxicol, 2015; 34: 135–44
62. Halliwell B: Reactive oxygen species and the central nervous system. J Neurochem, 1992; 59: 1609–23
63. Li JM, Mullen AM, Yun S et al: Essential role of the NADPH oxidase subunit p47(phox) in endothelial cell superoxide production in response to phorbol ester and tumor necrosis factor-alpha. Circ Res, 2002; 90: 143–50
64. Coyle CH, Kader KN: Mechanisms of H2O2-induced oxidative stress in endothelial cells exposed to physiologic shear stress. ASAIO J, 2007; 53: 17–22
65. Di Giovanni S, Eleuteri S, Paleologou KE et al: Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity. J Biol Chem, 2010; 285: 14941–54
66. Karamać M: Chelation of Cu(II), Zn(II), and Fe(II) by tannin constituents of selected edible nuts. Int J Mol Sci, 2009; 10: 5485–97
67. Prachayasittikul V, Prachayasittikul S, Ruchirawat S, Prachayasittikul V: 8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications. Drug Des Devel Ther, 2013; 7: 1157–78